These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1578318)

  • 41. The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults.
    Ziemniak JA; Assael BM; Padoan R; Schentag JJ
    Eur J Clin Pharmacol; 1984; 26(2):183-9. PubMed ID: 6723756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Removal of prednisone and prednisolone by plasma exchange.
    Stigelman WH; Henry DH; Talbert RL; Townsend RJ
    Clin Pharm; 1984; 3(4):402-7. PubMed ID: 6467876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prednisone and prednisolone bioavailability in renal transplant patients.
    Gambertoglio JG; Frey FJ; Holford NH; Birnbaum JL; Lizak PS; Vincenti F; Feduska NJ; Salvatierra O; Amend WJ
    Kidney Int; 1982 Apr; 21(4):621-6. PubMed ID: 7047863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cefepime pharmacokinetics in cystic fibrosis.
    Hamelin BA; Moore N; Knupp CA; Ruel M; Vallée F; LeBel M
    Pharmacotherapy; 1993; 13(5):465-70. PubMed ID: 8247913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration.
    Rohatagi S; Barth J; Möllmann H; Hochhaus G; Soldner A; Möllmann C; Derendorf H
    J Clin Pharmacol; 1997 Oct; 37(10):916-25. PubMed ID: 9505983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioavailability assessment of a liquid prednisone preparation.
    Georgitis JW; Flesher KA; Szefler SJ
    J Allergy Clin Immunol; 1982 Oct; 70(4):243-7. PubMed ID: 7119300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Comparative serum pharmacokinetics of prednisone and prednisolone methylsulfobenzoate after oral administration].
    Brion N; Pibarot ML; Atienza P; Robin P; Carbon C
    Presse Med; 1988 Apr; 17(12):569-71. PubMed ID: 2967477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of intravenous and oral prednisolone.
    Al-Habet S; Rogers HJ
    Br J Clin Pharmacol; 1980 Nov; 10(5):503-8. PubMed ID: 7437263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis.
    Alván G; Beermann B; Hjelte L; Lind M; Lindholm A; Strandvik B
    Clin Pharmacol Ther; 1988 Oct; 44(4):436-41. PubMed ID: 3168395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects.
    Konstan MW; Hoppel CL; Chai BL; Davis PB
    J Pediatr; 1991 Jun; 118(6):956-64. PubMed ID: 2040934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal handling of prednisolone/prednisone: effect of steroid dose and 11 beta-hydroxysteroid dehydrogenase.
    Conti M; Frey FJ; Escher G; Marone C; Frey BM
    Nephrol Dial Transplant; 1994; 9(11):1622-8. PubMed ID: 7870352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition.
    Frey BM; Sieber M; Mettler D; Gänger H; Frey FJ
    Drug Metab Dispos; 1988; 16(2):285-9. PubMed ID: 2898348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Theophylline disposition in cystic fibrosis.
    Isles A; Spino M; Tabachnik E; Levison H; Thiessen J; MacLeod S
    Am Rev Respir Dis; 1983 Apr; 127(4):417-21. PubMed ID: 6838048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study.
    de Groot R; Hack BD; Weber A; Chaffin D; Ramsey B; Smith AL
    Clin Pharmacol Ther; 1990 Jan; 47(1):73-8. PubMed ID: 2295222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The absence of effect of azathioprine on prednisolone pharmacokinetics following maintenance prednisone doses in kidney transplant patients.
    Gambertoglio JG; Holford HG; Lizak PS; Birnbaum JL; Salvatierra O; Amend WJ
    Am J Kidney Dis; 1984 May; 3(6):425-9. PubMed ID: 6372445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study.
    Levy J; Smith AL; Koup JR; Williams-Warren J; Ramsey B
    J Pediatr; 1984 Jul; 105(1):117-24. PubMed ID: 6376743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Montelukast pharmacokinetics in cystic fibrosis.
    Graff GR; Weber A; Wessler-Starman D; Smith AL
    J Pediatr; 2003 Jan; 142(1):53-6. PubMed ID: 12520255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prednisolone disposition in steroid-dependent asthmatic children.
    Rose JQ; Nickelsen JA; Ellis EF; Middleton E; Jusko WJ
    J Allergy Clin Immunol; 1981 Mar; 67(3):188-93. PubMed ID: 7462536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Altered metabolism and decreased efficacy of prednisolone and prednisone in patients with hyperthyroidism.
    Frey FJ; Horber FF; Frey BM
    Clin Pharmacol Ther; 1988 Nov; 44(5):510-21. PubMed ID: 2972434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tear Fluid Pharmacokinetics Following Oral Prednisone Administration in Dogs With and Without Conjunctivitis.
    Sebbag L; Yan Y; Smith JS; Allbaugh RA; Wulf LW; Mochel JP
    J Ocul Pharmacol Ther; 2019; 35(6):341-349. PubMed ID: 31070497
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.